Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell, PhD, President and COO of Agenus, will participate in a fireside chat at the BTIG Biotechnology Conference 2021 on Monday, August 9, 2021 from 3:00 p.m. to 3:25 p.m. ET.

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.

About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies through its MiNK Therapeutics subsidiary (formerly AgenTus Therapeutics), adjuvants, and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

ContactAgenus Investor RelationsJan Medina, CFAAgenus781-674-4490Jan.Medina@agenusbio.com

Agenus Media RelationsKimberly HaKKH Advisors917-291-5744kimberly.ha@kkhadvisors.com

 

Agenus (NASDAQ:AGEN)
Historical Stock Chart
Von Dez 2021 bis Jan 2022 Click Here for more Agenus Charts.
Agenus (NASDAQ:AGEN)
Historical Stock Chart
Von Jan 2021 bis Jan 2022 Click Here for more Agenus Charts.